PMID- 11908677
OWN - NLM
STAT- MEDLINE
DCOM- 20020404
LR  - 20051116
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 21
IP  - 6B
DP  - 2001 Nov-Dec
TI  - Hepatocyte growth factor expression in human cancer and therapy with specific 
      inhibitors.
PG  - 4243-52
AB  - Hepatocyte growth factor/Scatter Factor (HGF/SF) mediated stimulation of the Met 
      receptor tyrosine kinase results in pleiotropic cellular effects including 
      proliferation, morphogenesis, motility and invasion. In vivo, HGF/SF-Met 
      activation has been shown to participate in tumorigenesis, angiogenesis and 
      metastasis. Coupled with accumulating evidence that aberrant HGF/SF-Met 
      expression is frequently observed in a variety of human tumors, often in 
      association with progressive disease, these data present HGF/SF-Met as an 
      attractive target for therapeutic intervention in human cancer. In this review, 
      we will present the most compelling evidence suggesting a key role for HGF/SF-Met 
      signaling in tumorigenesis, and discuss several possible therapeutic strategies.
FAU - Haddad, R
AU  - Haddad R
AD  - Laboratory of Tumor Metastasis and Angiogenesis, Van Andel Research Institute, 
      Grand Rapids, MI 49503, USA.
FAU - Lipson, K E
AU  - Lipson KE
FAU - Webb, C P
AU  - Webb CP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 67256-21-7 (Hepatocyte Growth Factor)
SB  - IM
MH  - Animals
MH  - Hepatocyte Growth Factor/*antagonists & inhibitors/*biosynthesis/physiology
MH  - Humans
MH  - Neoplasms/*drug therapy/*metabolism
MH  - Signal Transduction/drug effects/physiology
RF  - 122
EDAT- 2002/03/23 10:00
MHDA- 2002/04/18 10:01
CRDT- 2002/03/23 10:00
PHST- 2002/03/23 10:00 [pubmed]
PHST- 2002/04/18 10:01 [medline]
PHST- 2002/03/23 10:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2001 Nov-Dec;21(6B):4243-52.